First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19
Udaya S. Tantry, Kevin P. Bliden, Alastair Cho, Naval Walia, Jeffrey R. Dahlen, Gordon Ens, Malina Traianova, Christophe Jerjian, Abira Usman, Paul A. Gurbel
Abstract
Abstract Urine 11-dehydro-thromboxane B2 (u11-dh-TxB2), 8-hydroxy-2’-deoxyguanosine (8-OHdG), and liver-type fatty acid binding protein levels (L-FABP) at the time of hospitalization were higher in coronavirus disease 2019 (COVID-19) patients with adverse events vs without events. Higher u11-dh-TxB2 and L-FABP levels were associated with longer hospitalization, more thrombotic events, and greater mortality, providing evidence for potential utility as early prognostic biomarkers for COVID-19.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Urinary systemInternal medicineUrineAdverse effectBiomarkerSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseIntensive care medicineGastroenterologyInfectious disease (medical specialty)BiochemistryChemistryCOVID-19 Clinical Research StudiesLiver Disease Diagnosis and TreatmentLipoproteins and Cardiovascular Health